HIGHLIGHTS
- who: Rosanne Ottevanger and colleagues from the Department of Dermatology, Leiden University Medical Center, Albinusdreef, ZA Leiden, The Netherlands have published the paper: Quality of Life in Cutaneous T-cell Lymphoma Patients Receiving Mogamulizumab: Important Factors to Consider, in the Journal: Cancers 2023, 15, 32. of 31/08/2021
- what: To assess treatment expectations, a 6-item questionnaire was developed for the purpose of this study, since expectations have to be tailored to the specific treatment outcome. This study shows that E-CTCL has a profound effect on the QoL. In general, this study has . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.